Reference Limits for Chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and Carcinoembryonic Antigen in Patients with Chronic Kidney Disease

Mikkelsen, Gustav; Åsberg, Arne; Hultström, Maria Elisabeth; Aasarød, Knut; Hov, Gunhild Garmo

doi:10.5301/ijbm.5000278

Cited by 12 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum concentrations of CgA correlated strongly with eGFR [32]. Its relationship with GFR is very similar to that of other substances eliminated by the kidney like creatinine and TATI [26].…”

Section: Discussionmentioning

confidence: 97%

Role of Serum Chromogranin A in Early Diagnosis of Diabetic Nephropathy

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Kidney is the main site for the removal of Chromogranin A (CgA). Previous studies have found that patients with renal impairment displayed elevated concentrations of CgA in plasma and the CgA concentrations reflect deterioration of renal function. In this study, we aimed to estimate the serum CgA levels and to evaluate the role of serum CgA in early diagnosis of diabetic nephropathy (DN).Methods: A total of 219 patients with type 2 diabetes mellitus (T2DM) were included in this cross-sectional study. They were classified into normoalbuminuria (n = 121), microalbuminuria (n = 73), or macroalbuminuria (n = 25) groups based on their urine albumin to creatinine ratios (UACR). A control group consisted of 45 healthy subjects. The serum CgA levels were measured by ELISA and other key parameters were assayed.Results: The serum CgA levels were higher in patients with T2DM compared to control subjects and a statistically significant difference among studied subgroups regarding CgA was found (P<0.05). Levels of serum CgA were increasing gradually with the degree of DN (P<0.001). Serum CgA levels were moderate intensity positively correlated with UACR (P<0.001). A cut-off level of 3.46 ng/ml CgA showed 69.86% sensitivity and 66.12% specificity to detect DN in early stage.Conclusions: Levels of serum CgA increased gradually with the degree of DN, and can be used as a biomarker in early detection of DN.

show abstract

Section: Discussionmentioning

confidence: 97%

Role of Serum Chromogranin A in Early Diagnosis of Diabetic Nephropathy

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The idea of disease-associated reference intervals is not new [ 1 , 2 , 5 , [7] , [8] , [9] , [18] , [19] , [20] ], but this is the first published study using LASSO selection of discharge diagnoses to identify patients without comorbidity significantly associated with high or low result values for specific laboratory tests in a general hospital population. The suggested reference intervals may be more representative for patients with RA, CD or UC than reference intervals based on healthy populations or on crude patient populations from which patients with relevant comorbidity have not been excluded.…”

Section: Discussionmentioning

confidence: 99%

Disease-associated reference intervals for twenty laboratory tests in patients with rheumatoid arthritis, Crohn’s disease or ulcerative colitis

Mikkelsen

Lillebo

Faxvaag

2021

Practical Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Background Population based reference intervals are fundamental for interpreting results for quantitative laboratory tests. In patients with a specific chronic disorder, however, results of various tests may regularly be different than in healthy individuals. Health-associated reference intervals may therefore have limited value in such patients. Instead, disease-associated reference intervals may be useful, as they describe the results distribution in populations resembling the specific patients. Few disease-associated reference intervals are available in the literature. The aim of this study was to estimate reference intervals for common laboratory tests for patient populations with rheumatoid arthritis, Crohn’s disease or ulcerative colitis without significant comorbidity, using a novel algorithm. Material and methods Laboratory test results and hospital discharge diagnoses were collected for relevant patients. An algorithm was developed to identify discharge diagnoses significantly associated with high or low results for specific tests. After excluding patients with such diagnoses, reference intervals were estimated, representing results distributions in patients with each of the specific chronic disorders, but without significant comorbidity. Results Disease-associated reference intervals were estimated for 20 common laboratory tests. Most of the estimated reference limits were significantly different from corresponding health-associated reference limits. Thirty percent of the estimated reference intervals were different from estimates based on crude patient populations, indicating that the algorithm applied managed to exclude patients with relevant comorbidity. Conclusion Disease-associated reference intervals could be estimated for a number of tests in patients with rheumatoid arthritis, ulcerative colitis or Crohn’s disease using a highly automated algorithm based on routinely recorded patient data.

show abstract

“…This effect of the PPIs is fully eliminated after discontinuation of the PPI for 2 weeks [38]. Chronic renal insufficiency (CRI) can also substantially increase the concentration of circulated CGA [39] and may led to concentrations of CGA as high as those detected in patients with neuroendocrine neoplasm [40]. Other diseases of the alimentary tract affecting CGA concentration are chronic gastritis [41], chronic hepatitis, liver cirrhosis [42], pancreatitis, irritable bowel, and inflammatory bowel diseases [43].…”

Section: Introductionmentioning

confidence: 99%

Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma

Bílek

Vlček

Safarík³

et al. 2019

Cancers

View full text Add to dashboard Cite

This work discusses the clinical performance of chromogranin A (CGA), a commonly measured marker in neuroendocrine neoplasms, for the diagnosis of pheochromocytoma/ paraganglioma (PPGL). Plasma CGA (cut-off value 150 µg/L) was determined by an immunoradiometric assay. Free metanephrine (cut-off value 100 ng/L) and normetanephrine (cut-off value 170 ng/L) were determined by radioimmunoassay. Blood samples were collected from PPGL patients preoperatively, one week, six months, one year and two years after adrenal gland surgery. The control patients not diagnosed with PPGL suffered from adrenal problems or from MEN2 and thyroid carcinoma. The clinical sensitivity in the PPGL group of patients (n = 71) based on CGA is 90% and is below the clinical sensitivity determined by metanephrines (97%). The clinical specificity based on all plasma CGA values after surgery (n = 98) is 99% and is the same for metanephrines assays. The clinical specificity of CGA in the control group (n = 85) was 92% or 99% using metanephrines tests. We can conclude that plasma CGA can serve as an appropriate complement to metanephrines assays in laboratory diagnosis of PPGL patients. CGA is elevated in PPGLs, as well as in other neuroendocrine or non-neuroendocrine neoplasia and under clinical conditions increasing adrenergic activity.

show abstract

Reference Limits for Chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and Carcinoembryonic Antigen in Patients with Chronic Kidney Disease

Cited by 12 publications

References 36 publications

Role of Serum Chromogranin A in Early Diagnosis of Diabetic Nephropathy

Role of Serum Chromogranin A in Early Diagnosis of Diabetic Nephropathy

Disease-associated reference intervals for twenty laboratory tests in patients with rheumatoid arthritis, Crohn’s disease or ulcerative colitis

Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma

Contact Info

Product

Resources

About